![No Picture](https://wallstreetanalyzer.com/wp-content/themes/mh-magazine/images/placeholder-content.png)
News Feed
POSITIVE DATA PRESENTED ON PIERIS PHARMACEUTICALS’ INHALED ASTHMA PROGRAM AT ERS AND COMPANY STRENGTHENS MANAGEMENT TEAM
PRECLINICAL DATA ON THE IL-4 RECEPTOR ANTAGONIST PRS-060 PRESENTED AT THE EUROPEAN RESPIRATORY SOCIETY CONFERENCE; MARY FITZGERALD, PH.D., TO LEAD PIERIS RESPIRATORY DRUG DEVELOPMENT PROGRAM […]